Gedeon Richter Plc. said on Tuesday that its financial outcomes for the third quarter and the first nine months of 2026 outperformed earlier expectations, prompting an upward revision to its full-year revenue and profit guidance.
On a constant exchange rate basis, the Budapest-based pharmaceutical group's pharma revenues increased 11.7% through the first nine months of 2026. In reported terms, pharma revenues rose 2.6% to HUF 686.5bn, a performance the company said was affected by roughly a 9 percentage-point currency headwind.
Profitability measures also showed improvement. Clean EBIT for the pharma business expanded 25% at constant exchange rates over the nine-month period. Measured on a reported basis, Clean EBIT climbed 8% to HUF 229.9bn.
The company attributed these results to several factors: the BIO division moving closer to breakeven, sustained strength in cariprazine franchise sales, and lower operating expenses driven by efficiency initiatives.
Net profit attributable to owners reached HUF 174.9bn in the first nine months, a 7.1% increase from the prior year. Free cash flow before mergers and acquisitions rose 12% to a record HUF 223bn.
Segment-level performance underpinned the top-line and margin gains. The central nervous system (CNS) segment saw revenues increase 19% at constant exchange rates, powered by Vraylar sales that AbbVie reported at $3.04bn, up 17% year-on-year. Reagila reported a 37% increase in sales at constant exchange rates.
Women’s Healthcare delivered an 11% revenue gain at constant exchange rates over the nine-month period, with acceleration to 19% growth in the third quarter. The company cited Ryeqo, Lenzetto and Drovelis as the principal contributors to that acceleration.
Meanwhile, BIO revenues rose 35% at constant exchange rates, supported by both biosimilar products and contract development and manufacturing organisation (CDMO) activities.
On the back of these developments, Gedeon Richter raised its 2026 outlook, upgrading revenue guidance to above 10% growth at constant exchange rates and lifting its Clean EBIT projection to high-teens growth.
The results show expanding cash generation and earnings momentum across Gedeon Richter’s core therapeutic areas, while reported results remain constrained by currency movements.